Kupiec James William
Known title: Chief Clinical Dev. OfficerCIK: 0001839551
Kupiec James William's purchase track record
Kupiec James William has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/23/2022 | FLNA | $61K | +30.0% | -0.4% | -3.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| FLNA | ▼ Sell | Open Market | 4,000 | $15K | 11/29/2024 | View on chart |
| FLNA | ▲ Buy | Option Exercise | 1,500 | $33K | 4/18/2024 | View on chart |
| FLNA | ▲ Buy | Open Market | 2,500 | $61K | 8/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
FLNA sees unusual volume and after-hours movement
Filana Therapeutics (FLNA) appeared on multiple lists for unusual trading volume and price gaps during recent sessions. The stock also showed notable movement in after-hours trading, drawing attention from market scanners. These technical signals suggest increased investor interest or reaction to recent developments, though no specific corporate news was provided in the data.
FLNA sees unusual volume and after-hours movement. Filana Therapeutics (FLNA) appeared on multiple lists for unusual trading volume and price gaps during recent sessions. The stock also showed notable movement in after-hours trading, drawing attention from market scanners. These technical signals suggest increased investor interest or reaction to recent developments, though no specific corporate news was provided in the data.